Compound library
Standardized profiles separate demonstrated human findings from early and theoretical claims.
Browse compoundsGathering the record
Loading the next view…
Relay is organizing the evidence and source boundaries.
Gathering the record
Relay is organizing the evidence and source boundaries.
Plain-English compound profiles, source-linked evidence, practical comparison tools, and community experience—with every type of information clearly labeled.
Start exploring
Begin with a clear overview. Open the science only when you want the methodology, limitations, and primary sources.
Standardized profiles separate demonstrated human findings from early and theoretical claims.
Browse compoundsSee the biggest practical and evidence differences without pretending indirect studies are head-to-head.
Compare compoundsExplore pathway coverage, receptor overlap, known combination evidence, and what remains unknown.
Explore a stackQuestion-led guides explain evidence, terminology, testing, and uncertainty before the details become useful.
Start with a guideNot sure where to begin?
Share your research goals. Relay will surface relevant compound profiles, explain why they matched those topics, and show where the evidence stops.
Compound profiles
Signal-biased dual GIP / GLP-1 receptor agonist
Enicepatide (CT-388 / RO7795068)
Enicepatide, formerly CT-388, is a once-weekly dual GIP/GLP-1 agonist. A 48-week sponsor-reported Phase 2 trial showed substantial weight loss, but full peer-reviewed Phase 2 reporting and Phase 3 outcomes remain pending.
Long-acting human amylin analogue
Petrelintide (ZP8396)
Petrelintide is a once-weekly amylin analogue designed to reduce appetite and body weight without GLP-1 receptor agonism. Phase 1 is peer reviewed and a 42-week Phase 2 trial has positive sponsor-reported results.
Unimolecular GLP-1 / amylin receptor co-agonist
Zenagamtide (formerly amycretin; NNC0487-0111)
Zenagamtide, formerly amycretin, combines GLP-1 and amylin receptor agonism in one molecule. Published early human and sponsor-reported Phase 2 results show substantial weight and glucose effects, alongside meaningful gastrointestinal tolerability and discontinuation concerns at higher doses.
Community counts come from approved, structured Experience Reports. Individual anonymous reports can appear immediately; aggregate patterns unlock only after the privacy threshold is met.
New core pillar · Tools
Use the familiar calculator, carry in a compound identity or build a completely custom vial, and see exactly how much of every user-entered component appears at each syringe mark.
Open Reconstitution HubThe relay gets stronger together
Account-linked Experience Reports can document distinct research periods and same-contributor follow-ups. Structured observations remain publicly anonymous by default, while written stories appear only with separate consent.
Explore Community Intelligence